HSC Exam Practice

Sample response. Negative feedback is a control mechanism in which a detected change in a variable (e.g. rising blood glucose after a meal) triggers a response (e.g. insulin release) that counteracts the original change and returns the variable toward its normal range (approximately 4–6 mmol/L in a healthy person).

Marking notes. 1 mark for identifying that the response counteracts or opposes the original change; 1 mark for correctly linking this to blood glucose regulation (rise detected → response reduces glucose back toward normal).

Sample response. In Type 2 diabetes the negative feedback loop is impaired, not absent. Blood glucose rises above the normal range after meals (stimulus detected), and the pancreas releases insulin (control centre responds). However, the effector cells — liver and muscle — respond weakly to insulin because of insulin resistance. Because the response is insufficient, blood glucose is only partially restored toward the set point. The feedback loop is operating but failing to correct the deviation effectively.

Marking notes. 1 mark for identifying that insulin is still released (loop is not absent); 1 mark for identifying insulin resistance in target cells as the reason the response is insufficient; 1 mark for explicitly stating that the variable is not restored to the normal range (partial/failed correction).

Sample response. Any two of: genetic predisposition (e.g. family history, inherited variants affecting insulin signalling or beta-cell function); age (risk increases significantly after 45); ethnicity (e.g. Aboriginal and Torres Strait Islander peoples, South Asian populations have higher genetic susceptibility); gestational diabetes history; polycystic ovary syndrome (PCOS).

Marking notes. 1 mark per valid non-lifestyle risk factor named and correctly identified as non-lifestyle (max 2). "Genetics" alone without elaboration scores 1 mark. Lifestyle factors (diet, inactivity, obesity without specifying genetic component) score 0.

Sample response. Chronic hyperglycaemia damages the endothelium of small blood vessels throughout the body, including the glomerular capillaries that filter blood in the kidney. As these capillaries are damaged (diabetic nephropathy), glomerular filtration rate declines and the kidney progressively loses its ability to remove waste products, regulate electrolyte balance and control fluid volume. This decline can progress to chronic kidney disease across stages, potentially reaching end-stage kidney failure requiring dialysis or transplantation.

Marking notes. 1 mark for identifying hyperglycaemia causing damage to small blood vessels / glomerular capillaries; 1 mark for explaining the consequence (declining filtration rate / kidney function loss); 1 mark for noting that progression can reach end-stage CKD requiring technology management. Marks may not be earned by vague statements such as "hurts the kidney" without mechanism.

Sample response. Incidence refers to the number of new cases of Type 2 diabetes diagnosed in a population over a specific time period (e.g. 120,000 new diagnoses in Australia in 2022). Prevalence refers to the total number of existing cases (both new and previously diagnosed) at a given point in time (e.g. approximately 1.3 million Australians living with Type 2 diabetes in 2022).

Marking notes. 1 mark for incidence = new cases over a time period; 1 mark for prevalence = total existing cases at a point in time. Marks lost if the student confuses the two definitions.

Sample response. Haemodialysis removes waste products and excess fluid from the blood by passing it through an artificial semipermeable membrane in a dialysis machine, using diffusion and ultrafiltration — partially compensating for lost glomerular filtration. Its key limitation is that it requires treatment approximately three times per week, creating intervals when toxins accumulate; it also does not restore kidney function, reduces quality of life through time burden, and requires vascular access. Kidney transplantation involves surgically implanting a donor kidney that, if successful, restores near-normal filtration and endocrine function, providing much better five-year survival (~85%) and quality of life compared to dialysis. Its limitations include the need for lifelong immunosuppressive medication (increasing infection risk), the unpredictability of organ availability (5–7-year wait in some Australian states), and the surgical risks of the procedure itself. Unlike dialysis, successful transplantation replaces lost function rather than compensating for it.

Marking notes. 1 mark for the biological mechanism of haemodialysis (diffusion across semipermeable membrane removing wastes/fluid); 1 mark for a specific, biologically accurate limitation of haemodialysis; 1 mark for the biological mechanism of transplantation (functional kidney restores filtration); 1 mark for a specific limitation of transplantation (immunosuppression, waitlist, surgical risk, or access). Award all 4 marks only if both technologies are addressed.

Sample response (a). The data shows a clear positive association between remoteness and Type 2 diabetes prevalence. Prevalence increases progressively across all five remoteness categories — from 5.1% in major cities to 14.3% in very remote areas, an almost threefold difference. Every step outward from major cities corresponds to a higher prevalence figure, suggesting a consistent gradient.

Sample response (b). The data shows an association between remoteness and higher T2D prevalence but cannot, by itself, prove that living in a remote area causes Type 2 diabetes. The graph is cross-sectional (a snapshot at one point in time) and does not demonstrate a causal relationship. Multiple confounding variables are likely: remoteness is correlated with lower socioeconomic status (affecting food security, healthcare access), a higher proportion of Aboriginal and Torres Strait Islander peoples who face both genetic and social determinants of higher T2D risk, lower physical activity options, and reduced access to preventive health services. Any of these confounders, individually or in combination, could explain the regional gradient without location itself being a cause. A causal claim would require longitudinal study designs that control for these confounders or intervention studies that isolate the effect of location.

Marking notes. Part (a): 1 mark for identifying the positive/increasing trend from major cities to very remote; 1 mark for supporting with at least one specific figure from the data. Part (b): 1 mark for identifying the key epidemiological limitation (correlation ≠ causation; cross-sectional design); 1 mark for naming at least two relevant confounders; 1 mark for stating what study design would be needed to establish causation.

Sample response (a). Improvement at 1000 Hz = 100 dB HL − 28 dB HL = 72 dB HL improvement. [1 mark — correct calculation]

Sample response (b). The cochlear implant has produced a substantial and clinically significant improvement in hearing threshold at all four frequencies tested — reductions of 60–75 dB HL across the range, bringing thresholds from the profound loss range (95–110 dB) into the mild loss range (28–35 dB). However, the claim that it has "restored normal hearing" is not supported by the data: at all four frequencies, the post-activation thresholds (28–35 dB HL) remain above the normal threshold of ≤25 dB HL. Furthermore, cochlear implants work by electrically stimulating the auditory nerve rather than restoring the damaged cochlear hair cells that caused the original sensorineural hearing loss — they bypass the damaged biology rather than repairing it. The device therefore significantly improves hearing function and quality of life, but does not recreate the full frequency resolution or dynamic range of normal cochlear function. A more accurate claim is that the implant has partially compensated for the lost function to a degree that significantly improves communicative ability, while a residual mild hearing loss remains.

Marking notes. Part (a): 1 mark for correct calculation (72 dB HL); no mark if arithmetic is wrong. Part (b): 1 mark for using data to show thresholds remain above ≤25 dB normal; 1 mark for explaining the mechanism (electrical stimulation of auditory nerve rather than repair of hair cells — compensates, not restores); 1 mark for a clear evaluative conclusion (significant functional improvement, not full restoration of normal biology).

Sample response. The statement contains three scientific flaws. First, it commits the epidemiological error of treating association as causation: while strong epidemiological data do show that T2D patients have much higher rates of CKD, this association — even if robust — does not by itself prove causation. The relationship is consistent with a causal pathway (hyperglycaemia → glomerular damage), but the statement's phrasing "this proves that diabetes causes kidney disease" overstates what association data alone can demonstrate. Second, the statement creates a false dichotomy by claiming that identifying a cause makes intervention technologies unnecessary. Even with effective diabetes control, many patients will already have progressed to advanced CKD or end-stage disease before or despite treatment — for these patients, dialysis is essential for survival and cannot be dismissed as irrelevant. Third, the claim that cochlear implants are "irrelevant" for this patient population is biologically incorrect: sensorineural hearing loss in patients with long-standing T2D can be caused by vascular damage to the cochlea independent of kidney disease progression, and cochlear implants address this loss by stimulating the auditory nerve — a separate therapeutic need from glucose or kidney management. The correct understanding is that epidemiological data support a causal link between hyperglycaemia and CKD through a specific biological mechanism, that better glucose control is an important prevention strategy (IQ4), and that management technologies (IQ5) remain essential for patients in whom disease has already progressed — prevention and technology are complementary, not mutually exclusive.

Marking notes. 1 mark for identifying the causation-from-association error and explaining why association alone does not prove cause; 1 mark for refuting the false dichotomy — dialysis remains essential for those who have already reached advanced CKD regardless of the cause; 1 mark for correctly explaining why cochlear implants are relevant (separate mechanism, cochlear vascular damage, independent of CKD); 1 mark for a correct account of the actual causal pathway (hyperglycaemia → vascular damage → glomerular injury → CKD); 1 mark for an integrated conclusion that frames prevention and technology as complementary, using Module 8 Inquiry Question language.

Sample response. Technologies are important but not the most important factor in managing chronic non-infectious disease — this claim overstates the role of technology and undervalues the broader management framework that integrates homeostatic understanding, multidisciplinary prevention, and patient-centred care. A justified evaluation requires examining what technologies actually do, what they cannot do, and what other factors matter more at earlier stages of disease.

The 55-year-old patient in the Module 8 case study has Type 2 diabetes with early chronic kidney disease, sensorineural hearing loss, and a family history of bowel cancer — a constellation of comorbidities that illustrates why no single technology can be "the most important factor". Homeostasis provides the fundamental framework: his blood glucose negative feedback loop is failing because target cells are insulin-resistant, leaving blood glucose persistently above the normal range. This chronic hyperglycaemia drives vascular damage, reducing glomerular filtration rate over time and progressing toward end-stage CKD. This pathway shows that the biological problem — failure of glucose homeostasis — is the root cause, not the absence of technology.

Dialysis is a critically important technology for patients who have already reached end-stage CKD: haemodialysis removes metabolic wastes (urea, creatinine) and excess fluid by diffusion across a semipermeable membrane approximately three times per week, sustaining life when kidneys can no longer filter adequately. Kidney transplantation, when successful, restores near-normal glomerular filtration and provides substantially better five-year survival (~85%) and quality of life than dialysis. Both are irreplaceable for patients at late disease stages. However, neither cures the underlying cause, and both work best when supplemented by continued glucose and blood pressure management. Dialysis, in particular, only compensates partially — intervals between sessions allow toxin accumulation, and the peritoneum degrades over time in peritoneal dialysis.

Cochlear implants similarly manage hearing loss caused by sensorineural damage (e.g. cochlear vascular injury associated with long-standing diabetes) by electrically stimulating the auditory nerve, significantly improving communicative function. They do not, however, restore normal cochlear hair cell biology or full frequency resolution — they compensate rather than repair.

Prevention strategies often have greater long-term impact than technologies because they act earlier in the disease pathway, before irreversible organ damage has accumulated. For this patient, improved glycaemic control (achieving HbA1c ≤7% through structured multidisciplinary care), blood pressure management, diet optimisation, and the National Bowel Cancer Screening Program (as a prevention technology) could slow or prevent the cascade from insulin resistance to kidney failure and cancer. Australian data from the AIHW consistently show that earlier intervention in glucose homeostasis reduces the rate of CKD progression. Epidemiological studies linking regional disadvantage to higher chronic disease burden (as in this patient's likely context) indicate that access, health literacy and social determinants must also be addressed — factors that no dialysis machine or cochlear implant can compensate for if patients cannot access or use them.

The evaluation therefore rejects the claim as stated. Technologies are essential and often life-preserving — especially for patients who have already progressed to late-stage disease — but they are most effective as part of a management continuum that places homeostatic understanding and prevention at the centre. For this patient, the most important factors across his care are: understanding and addressing the failed glucose feedback loop (IQ1), managing the interacting risk factors for each disease (IQ2), using epidemiological evidence to identify and address access barriers (IQ3), prioritising prevention and screening (IQ4), and deploying technologies as targeted support where disease has already progressed (IQ5). Technologies are a crucial layer, not the primary one.

Marking criteria.

• 1 mark — States a clear evaluative position that neither simply accepts nor blanket-rejects the statement (e.g. "technologies are important but not the primary factor; their value is stage-dependent").
• 1 mark — Links homeostasis to the case patient: explains the failed blood glucose negative feedback loop (insulin resistance → hyperglycaemia remains above normal range).
• 1 mark — Explains the mechanism of one named technology (dialysis: diffusion across semipermeable membrane; OR cochlear implant: electrical stimulation of auditory nerve).
• 1 mark — Explains the mechanism of a second named technology.
• 1 mark — Identifies a specific limitation for each technology that shows they compensate for, not cure, the disease (e.g. dialysis does not restore filtration; cochlear implant does not restore hair cells).
• 1 mark — Describes at least one named prevention strategy and explains why it matters more than or complements technology (e.g. HbA1c management slows CKD progression; bowel cancer screening reduces mortality earlier in the disease pathway).
• 1 mark — Uses epidemiological reasoning: identifies how population data guides where prevention resources should be directed, referencing regional access or health equity.
• 1 mark — Integrates all five Inquiry Questions coherently within the response (not as separate fragments, but as a connected argument).
• 1 mark — Reaches an explicit, defended final judgement explaining why the claim is an overstatement and what the correct balance of factors is.
• 1 mark — Response demonstrates Band 6 quality: mechanism → consequence → evidence → judgement logic; avoids overclaiming; uses precise Module 8 terminology throughout.